Neuropathix, Inc.
NPTX · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.11 | 0.12 | -0.03 |
| FCF Yield | -22.74% | -9.04% | -0.62% | -1.47% |
| EV / EBITDA | -2.00 | -2.78 | -230.43 | 2,049.24 |
| Quality | ||||
| ROIC | 243.64% | 505.06% | 709.44% | -22.75% |
| Gross Margin | 100.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.25 | 0.21 | 0.55 | -1.30 |
| Growth | ||||
| Revenue 3-Year CAGR | 11,233.73% | -100.00% | 377.99% | 70.68% |
| Free Cash Flow Growth | 5.09% | 51.23% | -59.48% | -5,115.59% |
| Safety | ||||
| Net Debt / EBITDA | -0.65 | -0.38 | -0.71 | 20.99 |
| Interest Coverage | -6.77 | -4.84 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 1.16 | 243.54 |